TTD | Drug: D0N8QK

Drug General Information
Drug ID	D0N8QK
Former ID	DNCL001986
Drug Name	ABT-288
Drug Type	Small molecular drug
Indication	Alzheimer disease; Schizophrenia [ICD9: 331, 295; ICD10:G30, F20]		Phase 2	[522864], [541972]
Company	Abbott Laboratories
Structure		Download 2D MOL
Formula	C23H24N4O
InChI	InChI=1S/C23H24N4O/c1-25-15-19-12-14-26(22(19)16-25)20-8-4-17(5-9-20)18-6-10-21(11-7-18)27-23(28)3-2-13-24-27/h2-11,13,19,22H,12,14-16H2,1H3/t19-,22+/m1/s1
InChIKey	GNIRITULTPTAQW-KNQAVFIVSA-N
PubChem Compound ID	24743471
PubChem Substance ID	49637031, 56161009, 137527961, 144233349, 163691800, 178103509, 224130140, 228520356, 246475817
Target and Pathway
Target(s)	Histamine H3 receptor	Target Info	Modulator
KEGG Pathway	Neuroactive ligand-receptor interaction
Reactome	Histamine receptors
Reactome	G alpha (i) signalling events
WikiPathways	Monoamine Transport
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522864	ClinicalTrials.gov (NCT01018875) Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 541972	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6927).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information